Randomized Trial: Alirocumab for Secondary Prevention of Cardiovascular Disease
10 Feb, 2019 | 13:57h | UTCCommentary: Alirocumab reduces risk of initial and repeat CV events after ACS – Cardiovascular Business (free)
Original Research: Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (link to abstract and commentaries)